GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Debt-to-Equity

Cue Biopharma (Cue Biopharma) Debt-to-Equity : 0.43 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Debt-to-Equity?

Cue Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $7.17 Mil. Cue Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $5.82 Mil. Cue Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $30.04 Mil. Cue Biopharma's debt to equity for the quarter that ended in Mar. 2024 was 0.43.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cue Biopharma's Debt-to-Equity or its related term are showing as below:

CUE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09   Med: 0.15   Max: 0.4
Current: 0.4

During the past 9 years, the highest Debt-to-Equity Ratio of Cue Biopharma was 0.40. The lowest was 0.09. And the median was 0.15.

CUE's Debt-to-Equity is ranked worse than
70.99% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs CUE: 0.40

Cue Biopharma Debt-to-Equity Historical Data

The historical data trend for Cue Biopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Debt-to-Equity Chart

Cue Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.11 0.09 0.15 0.29 0.40

Cue Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.39 0.38 0.40 0.43

Competitive Comparison of Cue Biopharma's Debt-to-Equity

For the Biotechnology subindustry, Cue Biopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Debt-to-Equity falls into.



Cue Biopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cue Biopharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Cue Biopharma's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cue Biopharma  (NAS:CUE) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Cue Biopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Cue Biopharma (Cue Biopharma) Business Description

Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
Executives
Anish Suri officer: President and CSO 40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri director, officer: CEO 40 GUEST STREET, BOSTON MA 02135
Pamela Garzone director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener director 40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti officer: Chief Medical Officer C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn officer: Chief Business Officer C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar officer: CFO 40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta officer: Chief Medical Officer C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin officer: SVP, General Counsel and Sec 40 GUEST STREET, BOSTON MA 02135
Tamar D Howson director
Barry J. Simon director 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll director